SG11202000247SA - Neoantigen vaccine composition for treatment of cancer - Google Patents

Neoantigen vaccine composition for treatment of cancer

Info

Publication number
SG11202000247SA
SG11202000247SA SG11202000247SA SG11202000247SA SG11202000247SA SG 11202000247S A SG11202000247S A SG 11202000247SA SG 11202000247S A SG11202000247S A SG 11202000247SA SG 11202000247S A SG11202000247S A SG 11202000247SA SG 11202000247S A SG11202000247S A SG 11202000247SA
Authority
SG
Singapore
Prior art keywords
cancer
treatment
vaccine composition
neoantigen vaccine
neoantigen
Prior art date
Application number
SG11202000247SA
Other languages
English (en)
Inventor
Alfredo Nicosia
Elisa Scarselli
Anna Morena D'alise
Original Assignee
Nouscom Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nouscom Ag filed Critical Nouscom Ag
Publication of SG11202000247SA publication Critical patent/SG11202000247SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
SG11202000247SA 2017-07-12 2018-07-12 Neoantigen vaccine composition for treatment of cancer SG11202000247SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17181026 2017-07-12
EP17200036 2017-11-03
PCT/EP2018/069047 WO2019012091A1 (en) 2017-07-12 2018-07-12 NEOANTIGEN-BASED VACCINE COMPOSITION FOR THE TREATMENT OF CANCER

Publications (1)

Publication Number Publication Date
SG11202000247SA true SG11202000247SA (en) 2020-02-27

Family

ID=62904488

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000247SA SG11202000247SA (en) 2017-07-12 2018-07-12 Neoantigen vaccine composition for treatment of cancer

Country Status (12)

Country Link
US (1) US20200230220A1 (ja)
EP (1) EP3651798A1 (ja)
JP (1) JP7298926B2 (ja)
KR (1) KR20200027499A (ja)
CN (1) CN111093699A (ja)
AU (1) AU2018300051A1 (ja)
BR (1) BR112020000581A2 (ja)
CA (1) CA3069051A1 (ja)
IL (1) IL271965B2 (ja)
MX (1) MX2020000414A (ja)
SG (1) SG11202000247SA (ja)
WO (1) WO2019012091A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018358019B2 (en) * 2017-11-03 2023-05-11 Nouscom Ag Vaccine T cell enhancer
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
CN113181351A (zh) * 2021-04-28 2021-07-30 广州赛佰澳生物医药科技有限公司 一种个体化肿瘤治疗性疫苗及其制备方法
TWI827057B (zh) * 2021-05-18 2023-12-21 中國醫藥大學 疫苗、其用途及癌症疫苗混合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170850A1 (en) * 2002-03-09 2003-09-11 Cardone Michael H. Cell-based screening methods
CN107723298A (zh) 2004-01-23 2018-02-23 Msd意大利有限公司 黑猩猩腺病毒疫苗载运体
US20100278904A1 (en) * 2005-11-30 2010-11-04 Copenhagen University Nucleotide vaccine
WO2010057501A1 (en) 2008-11-21 2010-05-27 Københavns Universitet (University Of Copenhagen) Priming of an immune response
CN101481675B (zh) * 2009-01-06 2011-09-14 武汉大学 一种抗猪瘟多表位dna疫苗及构建方法和应用
KR101763093B1 (ko) 2009-02-02 2017-07-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 시미안 아데노바이러스 핵산- 및 아미노산-서열, 이를 포함하는 벡터 및 이의 용도
JP6088488B2 (ja) * 2011-04-21 2017-03-01 シアトル ジェネティックス， インコーポレイテッド 新規な結合剤−薬物複合体（ａｄｃ）およびそれらの使用
CA2836494C (en) 2011-05-24 2023-01-03 Biontech Ag Individualized vaccines for cancer
WO2014139587A1 (en) * 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
CN103159860B (zh) * 2013-04-07 2014-09-24 旭华（上海）生物研发中心有限公司 重组组织型纤溶酶原激活剂及其制备方法与用途
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
US11186615B2 (en) 2015-10-08 2021-11-30 The Governors Of The University Of Alberta Hepatitis C virus E1/E2 heterodimers and methods of producing same
WO2017118702A1 (en) * 2016-01-08 2017-07-13 Vaccibody As Neoepitope rna cancer vaccine

Also Published As

Publication number Publication date
AU2018300051A1 (en) 2020-01-02
KR20200027499A (ko) 2020-03-12
US20200230220A1 (en) 2020-07-23
CA3069051A1 (en) 2019-01-17
WO2019012091A1 (en) 2019-01-17
RU2019144531A (ru) 2021-08-12
BR112020000581A2 (pt) 2020-07-14
CN111093699A (zh) 2020-05-01
RU2019144531A3 (ja) 2021-08-12
NZ759944A (en) 2023-08-25
IL271965B (en) 2022-11-01
EP3651798A1 (en) 2020-05-20
IL271965A (en) 2020-02-27
JP7298926B2 (ja) 2023-06-27
MX2020000414A (es) 2020-09-28
JP2020532287A (ja) 2020-11-12
IL271965B2 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
IL258955A (en) Preparations and methods for the treatment of cancer
IL268814A (en) Preparations and methods for the treatment of cancer
PL3458052T3 (pl) Leczenie skojarzone nowotworu
IL285077A (en) Compounds for the treatment of cancer
HK1247931A1 (zh) 用於診斷和治療癌症的組合物和方法
HK1251009B (zh) 用於治療癌症的治療組合物
IL271965A (en) Preparations containing a neoantigenic vaccine for the treatment of cancer
IL263793A (en) Compounds and preparations for the treatment of cancer
IL263835A (en) Exosome-guided treatment of cancer
IL261278A (en) Pharmaceutical compositions for the treatment of cancer
ZA201801022B (en) Syd985 treatment of t-dm1 refractory cancer patients
IL274748A (en) Improved cancer treatment
IL255167A0 (en) Compounds for the treatment of cancer
HK1259029A1 (zh) 用於治療癌症的具有抗趨除特性的組合物
GB201819943D0 (en) Immunotherapeutic treatment of cancer
GB201704287D0 (en) Treatment of cancer
GB201703857D0 (en) Treatment of cancer
GB201702565D0 (en) Treatment of cancer
GB201704474D0 (en) Combination therapy for treatment of cancer
GB201622214D0 (en) treatment of cancer
GB201702139D0 (en) Methods of cancer treatment
GB201604621D0 (en) Treatment of cancer
GB201604293D0 (en) Treatment of cancer
IL236381A0 (en) Pharmaceutical preparations for the treatment of cancer
GB201512723D0 (en) Treatment of cancer